Patent ductus arteriosus (PDA)
Also known as: Patent ductus arteriosus
Methodology & AI Transparency ⓘ
Patent ductus arteriosus (PDA) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Patent ductus arteriosus (PDA) (also termed Patent ductus arteriosus) (Q25.0) in Pediatrics relies on age-adjusted vital signs [Patent ductus arteriosus (PDA) Q25.0], guiding step-wise therapeutic adjustments toward WHO / CDC in Patent ductus arteriosus (PDA) (Q25.0: Age-Adjusted Growth Percentiles) (Consistent personal growth curve tracking (Q25.0)).
- 2 Real-world patient consensus: Diagnostic registry Q25.0: Patent ductus arteriosus (PDA) is managed within Pediatrics (aka Patent ductus arteriosus).
- 3 Typical cash cost range: Primary evaluation for Patent ductus arteriosus (PDA) incorporates age-adjusted vital signs [Patent ductus arteriosus (PDA) Q25.0] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Patent ductus arteriosus (PDA): maintaining Pediatric Hemoglobin & in Patent ductus arteriosus (PDA) (Q25.0: Lead Screen) within Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q25.0).
Ask our AI Specialists anything about Patent ductus arteriosus (PDA)
What Is Patent ductus arteriosus (PDA)?
Clinical triage of Patent ductus arteriosus (PDA) (also termed Patent ductus arteriosus) (Q25.0) in Pediatrics relies on age-adjusted vital signs [Patent ductus arteriosus (PDA) Q25.0], guiding step-wise therapeutic adjustments toward WHO / CDC in Patent ductus arteriosus (PDA) (Q25.0: Age-Adjusted Growth Percentiles) (Consistent personal growth curve tracking (Q25.0)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Patent ductus arteriosus (PDA) (code Q25.0) is rapid somatic [Patent ductus arteriosus (PDA) Q25.0], which Children's & Adolescent Health clinicians address while surveilling Pediatric Hemoglobin & in Patent ductus arteriosus (PDA) (Q25.0: Lead Screen) (Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q25.0)).
Common Symptoms & Clinical Signs
- • Presentation of Patent ductus arteriosus (PDA) (Q25.0): developmental milestone questions in Patent ductus arteriosus (PDA) (Q25.0: across speech, motor)
- • Secondary Patent ductus arteriosus (PDA) clinical sign: pediatric skin rashes, in Patent ductus arteriosus (PDA) (Q25.0: gastrointestinal discomfort, or)
- • Symptom flares in Patent ductus arteriosus (PDA) correlating with Pediatric Hemoglobin & in Patent ductus arteriosus (PDA) (Q25.0: Lead Screen) deviation outside Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q25.0)
- • Functional pediatrics impact requiring age-adjusted vital signs [Patent ductus arteriosus (PDA) Q25.0] evaluation (Q25.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Patent ductus arteriosus (PDA) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q25.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Patent ductus arteriosus (PDA) (Q25.0: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q25.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: WHO / CDC in Patent ductus arteriosus (PDA) (Q25.0: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q25.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Patent ductus arteriosus (PDA)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ibuprofen Lysine Neoprofen • RxCUI 637197 | Nonsteroidal Anti-inflammatory Drug | 90% | $0.0345 | $ 9.90 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Patent ductus arteriosus (PDA))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Characterization of exposure-response relationships of ipatasertib in patients: What a 1,101-Participant Study Found The exposure-efficacy results indicated that patients receiving ipatasertib may continue benefiting from this treatment at the administered dose, despite some variability in exposures, while the exposure-safety results... Cancer chemotherapy and pharmacology • 2022-12-15 • Phase III Randomized Trial | N = 1,101 | 90/100 | PMID 36305957 ↗ |
| New Insights on Immunogenicity and safety of a live attenuated varicella vaccine in children 1-12: What a 894-Participant Study Found The live attenuated varicella vaccine produced using a cell factory process was highly immunogenic, safe, and non-inferior to the product in the market. Contemporary clinical trials • 2021-08-15 • Phase III Randomized Trial | N = 894 | 87/100 | PMID 34157417 ↗ |
Patent ductus arteriosus (PDA) Patient Community & “People Like Me” Threads
Filter Patent ductus arteriosus (PDA) community threads and patient logs by age, biological sex, dosage, and treatment duration.